Results Of a Phase 2 Randomized, Open-Label, Study Of Lower Doses Of Quizartinib (AC220; ASP2689) In Subjects With FLT3-ITD Positive Relapsed Or Refractory Acute Myeloid Leukemia (AML)

被引：27

作者：

Cortes, Jorge E.

Tallman, Martin S.

Schiller, Gary

Trone, Denise

Gammon, Guy

Goldberg, Stuart

Perl, Alexander E.

Marie, Jean Pierre

Martinelli, Giovanni

Levis, Mark

机构：

来源：

BLOOD | 2013年 / 122卷 / 21期

关键词：

D O I：

10.1182/blood.V122.21.494.494

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

494

引用

页数：2

共 50 条

[31] A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia [J].

Smith, Catherine C. ;

Levis, Mark J. ;

Frankfurt, Olga ;

Pagel, John M. ;

Roboz, Gail J. ;

Stone, Richard M. ;

Wang, Eunice S. ;

Severson, Paul L. ;

West, Brian L. ;

Le, Mai H. ;

Kayser, Sabine ;

Lam, Bao ;

Hsu, Henry H. ;

Zhang, Chao ;

Bollag, Gideon ;

Perl, Alexander E. .

BLOOD ADVANCES, 2020, 4 (08) :1711-1721

[32] Phase 3 study of quizartinib (AC220) monotherapy vs salvage chemotherapy (SC) in patients (pts) with FLT3-ITD+ acute myeloid leukemia (AML) refractory to or relapsed (R/R) after 1st-line treatment with or without hematopoietic stem cell transplant (HSCT) consolidation: the QuANTUM-R study [J].

Cortes, J. ;

Gammon, G. ;

Khaled, S. ;

Martinelli, G. ;

Kramer, A. ;

Steffen, B. ;

Hogge, D. ;

Jonas, B. A. ;

Dombret, H. ;

Perl, A. .

ANNALS OF ONCOLOGY, 2016, 27

[33] A Phase II Single-Arm Open-Labeled Study Evaluating Combination of Quizartinib and Omacetaxine Mepesuccinate (QUIZOM) in Newly Diagnosed or Relapsed/Refractory AML Carrying FlT3-ITD [J].

Zhang, Chunxiao ;

Leung, Garret M. K. ;

Tsui, Sze Pui ;

Ip, Ho-Wan ;

Ma, Edmond S. K. ;

Au, Chun Hang ;

Chan, Chris T. L. ;

Ng, Ka Lam Nelson ;

Yip, Sze Fai ;

Kho, Bonnie ;

Lee, Harold K. K. ;

Liu, Qing ;

Leung, Thomas Wing Yan ;

Kwong, Yok Lam ;

Leung, Anskar Yu Hung .

BLOOD, 2019, 134

[34] Results of a phase 2, multicenter, single-arm, open-label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia [J].

O'Brien, Maureen M. ;

Alonzo, Todd A. ;

Cooper, Todd M. ;

Levine, John E. ;

Brown, Patrick A. ;

Slone, Tamra ;

August, Keith J. ;

Benettaib, Bouchra ;

Biserna, Noha ;

Poon, Jennifer ;

Patturajan, Meera ;

Chen, Nianhang ;

Simcock, Mathew ;

Zimmerman, Linda ;

Kolb, E. Anders .

PEDIATRIC BLOOD & CANCER, 2021, 68 (07)

[35] A phase III randomized study of gilteritinib versus salvage chemotherapy in FLT3 mutation-positive subjects with relapsed or refractory acute myeloid leukemia [J].

Wang, J. ;

Li, J. ;

Tantiworawit, A. ;

Izuka, S. ;

Yamada, S. ;

Hill, J. ;

Rich, E. Shima ;

Bahceci, E. .

ANNALS OF ONCOLOGY, 2018, 29

[36] ASP2215 in Japanese Patients with Relapsed or Refractory Acute Myeloid Leukemia: Preliminary Results from a Phase 1 Open-Label, Dose-Escalation Study [J].

Naoe, Tomoki ;

Sakura, Toru ;

Kobayashi, Yukio ;

Usuki, Kensuke ;

Miyamoto, Toshihiro ;

Iida, Hiroatsu ;

Morita, Satoshi ;

Bahceci, Erkut ;

Kaneko, Masahito ;

Yamada, Shunsuke ;

Takeshita, Shigeru ;

Miyawaki, Shuichi .

BLOOD, 2015, 126 (23)

[37] Quality-Adjusted Time without Symptoms or Toxicity (Q-TWiST) Analysis of Quizartinib Vs Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML) [J].

Cortes, Jorge E. ;

Ganguly, Siddhartha ;

Khaled, Samer K. ;

Kramer, Alwin ;

Levis, Mark J. ;

Martinelli, Giovanni ;

Perl, Alexander E. ;

Russell, Nigel H. ;

Botteman, Marc ;

Shah, Ruchit ;

Luo, Linlin ;

Shun, Zhenming ;

Ray, Saurabh .

BLOOD, 2019, 134

[38] Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response Study [J].

Altman, Jessica K. ;

Perl, Alexander E. ;

Cortes, Jorge E. ;

Levis, Mark J. ;

Smith, Catherine C. ;

Litzow, Mark R. ;

Baer, Maria R. ;

Claxton, David F. ;

Erba, Harry P. ;

Gill, Stanley C. ;

Goldberg, Stuart L. ;

Jurcic, Joseph G. ;

Larson, Richard A. ;

Lui, Charles ;

Ritchie, Ellen K. ;

Sargent, Briana ;

Schiller, Gary J. ;

Spira, Alexander I. ;

Strickland, Stephen A. ;

Tibes, Raoul ;

Ustun, Celalettin ;

Wang, Eunice S. ;

Stuart, Robert K. ;

Baldus, Claudia D. ;

Rollig, Christoph ;

Neubauer, Andreas ;

Martinelli, Giovanni ;

Bahceci, Erkut .

BLOOD, 2015, 126 (23)

[39] Bisantrene in Combination with Fludarabine and Clofarabine As Salvage Therapy for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)- an Open-Label, Phase II, Study [J].

Danylesko, Ivetta ;

Shimoni, Avichai ;

Avigdor, Abraham ;

Kedmi, Meirav ;

Shem-Tov, Noga ;

Yerushalmi, Ronit ;

Sasson, Maya ;

Dominissini, Dan ;

Andersson, Borje S. ;

Nagler, Arnon .

BLOOD, 2023, 142

[40] Tyrosine Kinase Inhibitors (TKI) in Relapsed/Refractory (RR) Patients with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Confer Better Survival than Chemotherapy, Due to a Better Safety Profile [J].

Papayannidis, Cristina ;

Marconi, Giovanni ;

De Polo, Stefano ;

Ottaviani, Emanuela ;

Paolini, Stefania ;

Bochicchio, Maria Teresa ;

Nanni, Jacopo ;

Bertamini, Luca ;

Abbenante, Maria Chiara ;

Sartor, Chiara ;

Parisi, Sarah ;

Baldazzi, Carmen ;

Curti, Antonio ;

Martinelli, Giovanni .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 :S200-S200

← 1 2 3 4 5 →